Articles from Front Range Pharmaceuticals

Front Range Pharmaceuticals ("Front Range") today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to FRP-003, the company's investigational drug candidate, for the treatment of Long COVID. FDA's Division of Rheumatology and Transplant Medicine issued the designation on October 30, 2026, under the company's investigational new drug application (IND 182511).

Front Range Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for FRP-003, allowing the company to proceed with a Phase 2 clinical trial in adults with Long COVID. FDA notified the company in writing on September 30, 2026, that the study may proceed.